Clinical Research Directory
Browse clinical research sites, groups, and studies.
MYLUNG Consortium Study Protocol 2
Sponsor: US Oncology Research
Summary
This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Official title: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1002
Start Date
2020-12-29
Completion Date
2027-12
Last Updated
2025-04-10
Healthy Volunteers
No
Conditions
Locations (18)
Southern Cancer Center, PC
Daphne, Alabama, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
Woodlands Medical Specialists, PA
Pensacola, Florida, United States
Illinois Cancer Specialists
Niles, Illinois, United States
Maryland Oncology Hematology, P.A.
Silver Spring, Maryland, United States
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, United States
New York Oncology Hematology, P.C.
Albany, New York, United States
Oncology Hematology Care Clinical Trials, LLC
Cincinnati, Ohio, United States
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
Texas Oncology - West Texas
Abilene, Texas, United States
Texas Oncology- DFWW
Arlington, Texas, United States
Texas Oncology-Dallas Presbyterian Hospital
Dallas, Texas, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, United States
Texas Oncology-McAllen
McAllen, Texas, United States
Texas Oncology- Northeast Texas
Tyler, Texas, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
Virginia Oncology Associates
Newport News, Virginia, United States